```html

Opsoclonus‑Myoclonus Syndrome (OMS) – A Comprehensive Medical Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neurological disorder characterized by two hallmark features:

• Opsoclonus – rapid, multidirectional, involuntary eye movements (also called “dancing eyes”).
• Myoclonus – sudden, brief jerks of the limbs, trunk, or face.

These movements are usually accompanied by ataxia (loss of coordination), irritability, and sometimes behavioral changes or sleep disturbances. OMS is considered an autoimmune or paraneoplastic condition, meaning the body’s immune system attacks its own nervous tissue, often in response to an underlying tumor.

Who It Affects

• Children: The most common form is paraneoplastic OMS, usually linked to neuroblastoma. It typically appears between ages 6 months and 3 years.
• Adults: Often a post‑infectious or idiopathic autoimmune reaction. Adults may develop OMS after viral infections, vaccination, or in association with other autoimmune diseases.

Prevalence

OMS is extremely rare. Estimates suggest:

• ≈ 1 case per 10 million children per year in the United States (Mayo Clinic Proceedings, 2011).
• Adult incidence is even lower, with only a few hundred reported cases worldwide to date.

Symptoms

Symptoms can develop suddenly over days or progress over weeks. The presentation may vary between children and adults, but the core symptom cluster remains the same.

Neurological Manifestations

• Opsoclonus – chaotic, conjugate eye movements in all directions, not suppressed by fixation.
• Myoclonus – brief, shock‑like jerks affecting the arms, legs, trunk, or neck; may be stimulus‑sensitive.
• Ataxia – unsteady gait, difficulty with fine motor tasks (e.g., buttoning a shirt).
• Dysarthria – slurred or scanning speech due to cerebellar involvement.
• Hypotonia – reduced muscle tone, especially in infants.

Systemic and Behavioral Features

• Sleep disturbances (insomnia or excessive daytime sleepiness).
• Irritability, mood swings, or emotional lability; in children, this may be misinterpreted as “behavioral problems.”
• Feeding difficulties in infants due to poor coordination.
• Occasional autonomic signs: flushing, sweating, or heart‑rate variability.

Red‑Flag Symptoms Requiring Immediate Attention

• Sudden worsening of eye movements causing visual loss.
• Severe, uncontrolled myoclonus that interferes with breathing.
• Development of new focal neurological deficits (e.g., weakness, numbness).

Causes and Risk Factors

OMS is not a single disease entity but a syndrome with several identifiable triggers.

Paraneoplastic (Tumor‑Associated) OMS

• Neuroblastoma – the most common tumor linked to pediatric OMS, found in 30‑50 % of cases (CDC).
• Other tumors: small‑cell lung carcinoma, breast carcinoma, ovarian teratoma in adults.

Post‑infectious or Post‑vaccinal OMS

• Viral triggers: varicella‑zoster, Epstein‑Barr, influenza, COVID‑19.
• Rare reports after immunizations (e.g., MMR, influenza), though causality is not firmly established.

Idiopathic Autoimmune OMS

• No identifiable tumor or recent infection; presumed to involve antibodies against neuronal surface antigens (e.g., anti‑Ri, anti‑Hu, anti‑NMDAR).

Risk Factors

• Age < 3 years (pediatric form) or > 50 years (adult paraneoplastic form).
• Genetic predisposition to autoimmunity (e.g., HLA‑DRB1*03).
• Existing autoimmune disorders (e.g., systemic lupus erythematosus).

Diagnosis

Because OMS mimics other movement disorders, a structured evaluation is essential.

Clinical Assessment

• Detailed history focusing on onset, preceding infections, vaccinations, and possible tumor symptoms (e.g., abdominal mass, weight loss).
• Neurological exam documenting opsoclonus, myoclonus, ataxia, and speech changes.

Laboratory and Imaging Studies

1. Blood tests – CBC, metabolic panel, inflammatory markers (ESR, CRP), and auto‑antibody panels (anti‑Ri, anti‑Hu, anti‑NMDAR, VGKC complex).
2. CSF analysis – mild lymphocytic pleocytosis, elevated protein, oligoclonal bands; helps rule out infection.
3. Neuroimaging – MRI of brain (and spinal cord if indicated) to exclude structural lesions; often normal in OMS.
4. Whole‑body imaging for tumors – abdominal/pelvic ultrasound or MRI for neuroblastoma in children; CT chest/abdomen/pelvis or PET‑CT in adults to seek occult neoplasms.
5. Eye‑movement recordings – electro‑oculography can quantify opsoclonus severity for research or follow‑up.

Diagnostic Criteria (adapted from the International Pediatric Neurology Group)

A diagnosis of OMS is made when a patient meets all three core criteria:

• Opsoclonus (multidirectional, conjugate saccades).
• Myoclonus (spontaneous or stimulus‑sensitive).
• At least one of the following: ataxia, behavioral change, or sleep disturbance.

Supportive evidence includes positive tumor work‑up or identifiable autoimmune antibodies.

Treatment Options

Early, aggressive therapy improves neurological outcomes and reduces long‑term disability.

First‑Line Immunotherapy

• Corticosteroids – high‑dose IV methylprednisolone (30 mg/kg/day, max 1 g) for 3–5 days, followed by an oral taper over 4–6 weeks.
• Intravenous Immunoglobulin (IVIG) – 2 g/kg total, divided over 2–5 days; may be repeated every 4–6 weeks if needed.
• Plasma Exchange (PLEX) – 5–7 exchanges over 10–14 days; useful when rapid antibody removal is desired.

Second‑Line / Adjunctive Therapies

• Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly for 4 weeks; shown to reduce relapse rates in pediatric cohorts (JAMA Neurology, 2019).
• Cyclophosphamide – oral or IV, reserved for refractory cases.
• Mycophenolate mofetil or Azathioprine – long‑term immunosuppression to maintain remission.

Tumor‑Directed Treatment

If a neuroblastoma or other malignancy is identified, oncologic therapy (surgery, chemotherapy, or radiotherapy) is essential. Tumor removal frequently leads to neurological improvement, especially when combined with immunotherapy.

Symptomatic Management

• Anticonvulsants – clonazepam, levetiracetam, or valproic acid can modestly dampen myoclonus.
• Physical & occupational therapy – balance training, gait re‑education, and fine‑motor exercises.
• Sleep hygiene – consistent bedtime routine, limited caffeine, and, if needed, low‑dose melatonin.

Rehabilitation Timeline

Recovery is usually gradual:

• First 3 months – most improvement in eye movements and myoclonus.
• 6–12 months – gains in coordination and speech.
• Beyond 12 months – some children retain mild ataxia or learning difficulties; early educational interventions are critical.

Living with Opsoclonus‑Myoclonus Syndrome

Chronic management focuses on maximizing independence while monitoring for relapse.

Daily Management Tips

• Medication adherence – set alarms or use pill‑organizers; never stop steroids abruptly.
• Home safety – install grab bars, use non‑slip mats, and keep pathways clear to prevent falls.
• Vision strategies – use sunglasses or visual “filters” if opsoclonus interferes with reading; ensure regular ophthalmology visits.
• School & work accommodations – request extra time for tests, preferential seating, and physical‑therapy breaks.
• Psychosocial support – counseling, support groups, and cognitive‑behavioral therapy can address irritability and anxiety.

Follow‑Up Schedule

Time Post‑Diagnosis	Recommended Visits
First 3 months	Monthly neurologist, quarterly ophthalmology, tumor surveillance if applicable.
3–12 months	Every 2–3 months neurologist; imaging annually or sooner if symptoms recur.
After 1 year	Every 6 months; consider tapering immunosuppressants if stable.

Prevention

Because OMS is largely immune‑mediated, primary prevention is limited, but certain measures can reduce risk or detect disease early.

• Prompt evaluation of neuroblastoma – routine abdominal ultrasound in infants with unexplained neurological signs.
• Vaccination safety – vaccinations are safe for most; discuss concerns with a pediatrician if a child has a history of autoimmune disease.
• Infection control – good hand hygiene and timely treatment of viral illnesses may lower post‑infectious triggers.

Complications

If untreated or inadequately managed, OMS can cause long‑term sequelae.

• Persistent ataxia – may require lifelong physical therapy.
• Neurocognitive deficits – learning disabilities, attention‑deficit/hyperactivity disorder (ADHD), or language delays in children.
• Psychiatric disorders – anxiety, depression, or behavioral dysregulation.
• Relapse – up to 30 % of patients experience recurrence within 2 years, especially if immunotherapy is tapered too quickly.
• Side effects of treatment – steroid‑induced hyperglycemia, osteopenia, infection risk from immunosuppression.

When to Seek Emergency Care

References

• Mayo Clinic Proceedings. “Opsoclonus‑Myoclonus Syndrome: Clinical Features and Treatment.” 2011. PMCID: PMC3327864.
• JAMA Neurology. “Rituximab for Persistent Opsoclonus‑Myoclonus Syndrome in Children.” 2019. doi:10.1001/jamaneurol.2019.1075.
• Centers for Disease Control and Prevention (CDC). “Neuroblastoma Overview.” 2023. cdc.gov.
• National Institutes of Health (NIH). “Autoimmune Encephalitis Fact Sheet.” 2022. ninds.nih.gov.
• World Health Organization (WHO). “Guidelines for the Management of Paraneoplastic Neurologic Syndromes.” 2020.
• Cleveland Clinic. “Opsoclonus‑Myoclonus (Dancing Eyes‑Dancing Feet) Syndrome.” Updated 2024. clevelandclinic.org.

```